Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
US Judge Dismisses Gautam Adani Criminal Charges 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
ADNOC Gas Targets Up to $4B Profit in 2026 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Genetic testing company 23andMe Holding Co. (NASDAQ: ME) has filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the Eastern District of Missouri. The company announced the move on Monday, aiming to facilitate a court-supervised sale process while continuing operations.
The bankruptcy filing follows the rejection of a buyout offer from company co-founder Anne Wojcicki and her affiliates. Wojcicki has since stepped down as CEO but will stay on the board. Joe Selsavage has been appointed interim CEO to lead the company through the restructuring phase.
Facing mounting financial pressure and legal issues tied to a 2023 cybersecurity breach, 23andMe cited the Chapter 11 process as a necessary step to stabilize the business, reduce costs, and resolve outstanding liabilities. As part of the filing, the company secured $35 million in debtor-in-possession financing from JMB Capital Partners to maintain operations throughout the proceedings.
Despite the bankruptcy, 23andMe emphasized that customer data privacy and protection will remain intact and are a top priority during any asset sale. The company plans to solicit bids over a 45-day period, with any final transaction requiring regulatory approval.
Once a pioneer in at-home DNA testing, 23andMe has struggled with declining revenues, rising costs, and reputational damage following last year’s cyber incident. The firm is now seeking a buyer to preserve its core assets and continue its mission of delivering personalized genetic health insights.
This latest development marks a turning point for the once high-flying biotech firm, underscoring broader challenges in the consumer healthtech sector. Investors and customers alike will be closely watching as the company navigates its next chapter under bankruptcy protection.
